These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

118 related articles for article (PubMed ID: 11001233)

  • 21. Olanzapine: an updated review of its use in the management of schizophrenia.
    Bhana N; Foster RH; Olney R; Plosker GL
    Drugs; 2001; 61(1):111-61. PubMed ID: 11217867
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Olanzapine for the treatment of chronic refractory schizophrenia: a 12-month follow-up naturalistic study.
    Rodríguez-Pérez V; López A; Blanco C; Peña C; López A; Abel A; Gómez Y; Ferreiro MJ; Rego C; López A; Cudeiro F; Alvarez V; Prieto R; Ciudad A
    Prog Neuropsychopharmacol Biol Psychiatry; 2002 Oct; 26(6):1055-62. PubMed ID: 12452526
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A double-blind, randomised comparative trial of amisulpride versus olanzapine in the treatment of schizophrenia: short-term results at two months.
    Martin S; Lĵo H; Peuskens J; Thirumalai S; Giudicelli A; Fleurot O; Rein W;
    Curr Med Res Opin; 2002; 18(6):355-62. PubMed ID: 12442883
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Olanzapine versus haloperidol in the treatment of schizophrenia and schizoaffective and schizophreniform disorders: results of an international collaborative trial.
    Tollefson GD; Beasley CM; Tran PV; Street JS; Krueger JA; Tamura RN; Graffeo KA; Thieme ME
    Am J Psychiatry; 1997 Apr; 154(4):457-65. PubMed ID: 9090331
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Olanzapine compared with chlorpromazine in treatment-resistant schizophrenia.
    Conley RR; Tamminga CA; Bartko JJ; Richardson C; Peszke M; Lingle J; Hegerty J; Love R; Gounaris C; Zaremba S
    Am J Psychiatry; 1998 Jul; 155(7):914-20. PubMed ID: 9659857
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The effectiveness of olanzapine in treatment-refractory schizophrenia when patients are nonresponsive to or unable to tolerate clozapine.
    Dossenbach MRK ; Beuzen JN; Avnon M; Belmaker RH; Elizur A; Mark M; Munitz H; Schneidman M; Shoshani D; Kratky P; Grundy SL; Tollefson GD
    Clin Ther; 2000 Sep; 22(9):1021-34. PubMed ID: 11048902
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Comparative efficacy of olanzapine and haloperidol for patients with treatment-resistant schizophrenia.
    Breier A; Hamilton SH
    Biol Psychiatry; 1999 Feb; 45(4):403-11. PubMed ID: 10071708
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Amisulpride a selective dopamine antagonist and atypical antipsychotic: results of a meta-analysis of randomized controlled trials.
    Leucht S
    Int J Neuropsychopharmacol; 2004 Mar; 7 Suppl 1():S15-20. PubMed ID: 14972080
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The safety of olanzapine compared with other antipsychotic drugs: results of an observational prospective study in patients with schizophrenia (EFESO Study). Pharmacoepidemiologic Study of Olanzapine in Schizophrenia.
    Gómez JC; Sacristán JA; Hernández J; Breier A; Ruiz Carrasco P; Antón Saiz C; Fontova Carbonell E
    J Clin Psychiatry; 2000 May; 61(5):335-43. PubMed ID: 10847307
    [TBL] [Abstract][Full Text] [Related]  

  • 30. An integrated analysis of acute treatment-emergent extrapyramidal syndrome in patients with schizophrenia during olanzapine clinical trials: comparisons with placebo, haloperidol, risperidone, or clozapine.
    Carlson CD; Cavazzoni PA; Berg PH; Wei H; Beasley CM; Kane JM
    J Clin Psychiatry; 2003 Aug; 64(8):898-906. PubMed ID: 12927004
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A comparison of the effects of clozapine and olanzapine on the EEG in patients with schizophrenia.
    Schuld A; Kühn M; Haack M; Kraus T; Hinze-Selch D; Lechner C; Pollmächer T
    Pharmacopsychiatry; 2000 May; 33(3):109-11. PubMed ID: 10855462
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Effect of divalproex combined with olanzapine or risperidone in patients with an acute exacerbation of schizophrenia.
    Casey DE; Daniel DG; Wassef AA; Tracy KA; Wozniak P; Sommerville KW
    Neuropsychopharmacology; 2003 Jan; 28(1):182-92. PubMed ID: 12496955
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Modulation of brain and serum glutamatergic concentrations following a switch from conventional neuroleptics to olanzapine.
    Goff DC; Hennen J; Lyoo IK; Tsai G; Wald LL; Evins AE; Yurgelun-Todd DA; Renshaw PF
    Biol Psychiatry; 2002 Mar; 51(6):493-7. PubMed ID: 11922885
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Switching from depot antipsychotic drugs to olanzapine in patients with chronic schizophrenia.
    Godleski LS; Goldsmith LJ; Vieweg WV; Zettwoch NC; Stikovac DM; Lewis SJ
    J Clin Psychiatry; 2003 Feb; 64(2):119-22. PubMed ID: 12633119
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Olanzapine for schizophrenia.
    Duggan L; Fenton M; Dardennes RM; El-Dosoky A; Indran S
    Cochrane Database Syst Rev; 2000; (2):CD001359. PubMed ID: 10796640
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A double-blind, controlled comparison of the novel antipsychotic olanzapine versus haloperidol or placebo on anxious and depressive symptoms accompanying schizophrenia.
    Tollefson GD; Sanger TM; Beasley CM; Tran PV
    Biol Psychiatry; 1998 Jun; 43(11):803-10. PubMed ID: 9611669
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Dopamine D2 receptor occupancy by olanzapine or risperidone in young patients with schizophrenia.
    Lavalaye J; Linszen DH; Booij J; Reneman L; Gersons BP; van Royen EA
    Psychiatry Res; 1999 Nov; 92(1):33-44. PubMed ID: 10688158
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Olanzapine: a serotonin-dopamine-receptor antagonist for antipsychotic therapy.
    Bever KA; Perry PJ
    Am J Health Syst Pharm; 1998 May; 55(10):1003-16. PubMed ID: 9606451
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Neuroleptic malignant syndrome after addition of haloperidol to atypical antipsychotic.
    Mujica R; Weiden P
    Am J Psychiatry; 2001 Apr; 158(4):650-1. PubMed ID: 11282706
    [No Abstract]   [Full Text] [Related]  

  • 40. Atypical antipsychotics: new directions and new challenges in the treatment of schizophrenia.
    Kapur S; Remington G
    Annu Rev Med; 2001; 52():503-17. PubMed ID: 11160792
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.